Atypical hemolytic-uremic syndrome: Difference between revisions
From IDWiki
m (Aidan moved page Atypical hemolytic uremic syndrome to Atypical hemolytic-uremic syndrome without leaving a redirect) |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | == |
+ | ==Background== |
===Pathophysiology=== |
===Pathophysiology=== |
||
| Line 13: | Line 13: | ||
*Often unable to distinguish from TTP, so [[plasma exchange]] should be initiated promptly |
*Often unable to distinguish from TTP, so [[plasma exchange]] should be initiated promptly |
||
*If no improvement on PLEX and there is significant renal involvement, consider an aHUS-specific treatment |
*If no improvement on PLEX and there is significant renal involvement, consider an aHUS-specific treatment |
||
| − | **[[Eculizumab]] to inhibit complement |
+ | **[[Eculizumab]] to inhibit complement, ideally with full meningococcal vaccination beforehand |
[[Category:Hematology]] |
[[Category:Hematology]] |
||
Revision as of 07:30, 15 August 2020
Background
Pathophysiology
- Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity
Diagnosis
- Genetic mutation analysis of complement regulatory proteins (CFH, CFI, MCP, C3, CFB, THBD) and anti-CFH antibodies
Management
- Often unable to distinguish from TTP, so plasma exchange should be initiated promptly
- If no improvement on PLEX and there is significant renal involvement, consider an aHUS-specific treatment
- Eculizumab to inhibit complement, ideally with full meningococcal vaccination beforehand
